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Abstract
Background
Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP)
is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole
prophylaxis (CTXp) in HIV-positive women. Alternative antimalarials are required in areas
where parasite resistance to antifolate drugs is high. The cost-effectiveness of IPTp with al-
ternative drugs is needed to inform policy.
Methods
The cost-effectiveness of 2-dose IPTp-mefloquine (MQ) was compared with IPTp-SP in
HIV-negative women (Benin, Gabon, Mozambique and Tanzania). In HIV-positive women
the cost-effectiveness of 3-dose IPTp-MQ added to CTXp was compared with CTXp alone
(Kenya, Mozambique and Tanzania). The outcomes used were maternal clinical malaria,
anaemia at delivery and non-obstetric hospital admissions. The poor tolerability to MQ was
included as the value of women’s loss of working days. Incremental cost-effectiveness ra-
tios (ICERs) were calculated and threshold analysis undertaken.
PLOS ONE | DOI:10.1371/journal.pone.0125072 April 27, 2015 1 / 23
OPEN ACCESS
Citation: Sicuri E, Fernandes S, Macete E, González
R, Mombo-Ngoma G, Massougbodgi A, et al. (2015)
Economic Evaluation of an Alternative Drug to
Sulfadoxine-Pyrimethamine as Intermittent
Preventive Treatment of Malaria in Pregnancy. PLoS
ONE 10(4): e0125072. doi:10.1371/journal.
pone.0125072
Academic Editor: T. Mark Doherty, Glaxo Smith
Kline, DENMARK
Received: October 18, 2014
Accepted: March 15, 2015
Published: April 27, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: Data cannot be made
available due to ethical restrictions and restrictions in
the consent forms signed by participants. Data are
available upon request from Clara Menendez ( clara.
menendez@isglobal.org).
Funding: This study was supported by MiP
Consortium, which is funded through a grant from the
Bill & Melinda Gates Foundation to the Liverpool
School of Tropical Medicine.
Results
For HIV-negative women, the ICER for IPTp-MQ versus IPTp-SP was 136.30 US$ (2012
US$) (95%CI 131.41; 141.18) per disability-adjusted life-year (DALY) averted, or 237.78
US$ (95%CI 230.99; 244.57), depending on whether estimates from Gabon were included
or not. For HIV-positive women, the ICER per DALY averted for IPTp-MQ added to CTXp,
versus CTXp alone was 6.96 US$ (95%CI 4.22; 9.70). In HIV-negative women, moderate
shifts of variables such as malaria incidence, drug cost, and IPTp efficacy increased the
ICERs above the cost-effectiveness threshold. In HIV-positive women the intervention re-
mained cost-effective for a substantial (up to 21 times) increase in cost per tablet.
Conclusions
Addition of IPTp with an effective antimalarial to CTXp was very cost-effective in HIV-posi-
tive women. IPTp with an efficacious antimalarial was more cost-effective than IPTp-SP in
HIV-negative women. However, the poor tolerability of MQ does not favour its use as IPTp.
Regardless of HIV status, prevention of malaria in pregnancy with a highly efficacious, well
tolerated antimalarial would be cost-effective despite its high price.
Trials Registration
ClinicalTrials.gov NCT 00811421; Pan African Trials Registry PACTR2010020001429343
and PACTR2010020001813440
Introduction
The negative effects of malaria on economic growth and development in endemic countries are
well recognised [1, 2]. During pregnancy, malaria infection may have an adverse economic im-
pact through its harmful effects on maternal and infant health, which increase health system as
well as household costs, mainly due to clinical management of cases and to the long term con-
sequences of low birth weight [3–8]. The magnitude of this economic impact in the African re-
gion, where nearly 30 million pregnancies per year occur in areas of stable transmission of
Plasmodium falciparum, is likely to be significant [9].
To prevent malaria in pregnancy in Africa in areas with moderate to high transmission of
P. falciparum, the World Health Organization (WHO) recommends intermittent preventive
treatment (IPTp) with sulfadoxine-pyrimethamine (SP) and long lasting insecticide treated
nets (LLINs) [10]. In Africa, daily cotrimoxazole prophylaxis (CTXp) is recommended to avert
opportunistic infections in human immunodeficiency virus (HIV) positive pregnant women
[11]. However, the concomitant use of CTXp and SP is contraindicated due to the increased
risk of severe cutaneous reactions [12, 13].
The spread of parasite resistance to SP has raised concerns about the medium and long-
term use of this drug for IPTp particularly in south-eastern Africa [14, 15]. HIV adds complex-
ity to malaria prevention strategies as it increases the susceptibility to P. falciparum infection
and reduces the efficacy and effectiveness of antimalarial interventions [16]. Although CTXp
has been shown to protect against malaria infection in children and non-pregnant adults [17,
18], there is limited evidence of its efficacy in pregnant HIV-positive women [19]. For these
reasons, the evaluation of alternative antimalarials to SP for IPTp as well as strategies to
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prevent malaria in the particularly vulnerable group of HIV-positive pregnant women has be-
come a public health priority.
To help find alternatives to SP for HIV-negative women and to improve malaria prevention
in HIV-positive pregnant women, two multicentre clinical trials were designed to evaluate the
safety and efficacy of mefloquine (MQ) as IPTp. The trial in HIV-negative women conducted
in Benin, Gabon, Mozambique and Tanzania compared IPTp with MQ (15 mg/kg) versus SP
[20]. The trial in HIV-positive women conducted in Kenya, Mozambique and Tanzania com-
pared IPTp with MQ (15 mg/kg) versus placebo in women receiving daily CTXp [21]. In both
trials all women received a long lasting insecticide treated net (LLIN) as part of the study
interventions.
The findings from these studies showed the health benefits associated with MQ administra-
tion at the dosage of 15 mg/kg. However, tolerability and safety issues will limit the usefulness
of MQ, at that dosage, as IPTp [22, 23]. In brief, mainly dizziness and vomiting were signifi-
cantly more frequent in the MQ groups of both trials and, unexpectedly, in the trial in HIV-
positive women, HIV viral load at delivery was found to be higher and the rate of mother to
child transmission (MTCT) of HIV was increased in MQ recipients in an exploratory analysis.
Despite these concerns, the results from these trials served to provide inputs to model the cost-
effectiveness of using an alternative antimalarial drug as IPTp. The resulting economic evalua-
tion has estimated: (i) the incremental cost-effectiveness of an alternative antimalarial to SP as
IPTp for HIV-negative pregnant women; (ii) the incremental cost-effectiveness of IPTp with
an antimalarial compared to IPTp-placebo for HIV-positive pregnant women taking daily
CTXp; (iii) the threshold values of several variables, including drug efficacy and cost, beyond
which IPTp with an alternative antimalarial stops being cost-effective.
Methods
Ethics statement
The clinical trial study protocol and informed consent forms were reviewed and approved by
the Ethics Committees from the Hospital Clínic of Barcelona (Spain), the US CDC and the
local regulatory authorities and National Ethics Review Committees from Kenya, Mozambique
and Tanzania the Comité Consultatif de Déontologie et d’Ethique (CCDE) from the Institut de
Recherche pour le Développement (IRD, in France) and all local regulatory authorities and Na-
tional Ethics Review Committees from each endemic country participating in the study. The
trials were conducted under the provisions of the Declaration of Helsinki and in accordance
with Good Clinical Practices guidelines set up by the WHO and by the International Confer-
ence on Harmonization. The Ethics Committees waived the requirement for consent for addi-
tional ancillary analyses of trials data (including the cost effectiveness study). All participants
provided written informed consent for participation in the trials. The cost-effectiveness study
was designed, with its own separate protocol, in parallel to the development of the protocol of
the two clinical trials. The study was not based on individual level data from the trial partici-
pants and it was, thus, independent from the trial protocol. The cost-effectiveness study proto-
col was approved by the Ethics Committee of the London School of Hygiene and Tropical
Medicine; by the Institutional Review Boards of the Ifakara Health Institute (Tanzania) and of
the Manhiça Health Research Centre (Mozambique); and by the National Institute for Medical
Research in Tanzania.
Study areas and population
The trials were conducted between 2009 and 2013 in five sub-Saharan African countries: Benin
(Allada, Sékou, and Attogon), Gabon (Lamberéné and Fougamou), Kenya (Siaya), Tanzania
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(Makole and Chamwino) and Mozambique (Manhiça and Maragra). All sites were located ei-
ther in rural or in semi-rural areas with different malaria endemicities (S1 Table). The Gross
Domestic Product (GDP) per capita for the year 2012 of Benin, Kenya, Mozambique and Tan-
zania, ranged from a lowest value of US$ 565 (Mozambique) to a highest value of US$ 943
(Kenya). Gabon had the highest GDP per capita (US$ 11,257) [24].
Study design
The study in HIV-negative women was an open label randomized trial comparing 2-doses of
MQ (Lariam) as IPTp versus SP (Malastop). The study in HIV-positive women was a double
blind placebo controlled trial comparing 3-doses of MQ as IPTp versus placebo in women re-
ceiving daily cotrimoxazole (Septrin) prophylaxis. All women received a LLIN (PermaNet) [20,
21].
The economic evaluation of the two trials was based on incremental costs, net of health sys-
tem treatment cost savings, and health outcomes (Fig 1). Although they investigate the cost-ef-
fectiveness of the same strategy, namely IPTp-MQ, the two models are separate and
independent as they referred to different cohorts (HIV-negative and HIV-positive pregnant
women) and have different comparator strategies (IPTp-SP and IPTp-placebo). The outcomes
of the two models will be, thus, not comparable. As clinical trials were not designed to make
across site comparisons, results of the cost-effectiveness analyses will not be either reported or
compared across country [20, 21].
Study outcomes
The study outcomes used in this economic evaluation were derived from the intention to treat
analyses of the trials and were selected according to two pre-defined criteria, namely having a
direct health impact [25–27], and showing a statistically significant difference between the in-
tervention groups [28]. All trials outcomes are reported in S2–S5 Tables. In the trial in HIV-
negative women, the primary endpoint (prevalence of low birth weight babies) met the first cri-
terion but not the second one since no significant difference was found between MQ and SP
groups (Risk Ratio 1.02 (95%CI 0.86; 1.22); p = 0.801). In the trial in HIV-positive women, the
Fig 1. Design of the Incremental economic evaluation. HIV = Human Immunodeficiency Virus;
LLITNs = Long-Lasting Insecticide Treated Nets; CTX = Cotrimoxazole; IPTp = Intermittent Preventive
Treatment of malaria in pregnancy; SP = Sulphadoxine-Pyrimethamine; MQ =Mefloquine. The figure shows
that for both Trials the cost of LLITNs was not considered in the economic evaluation performed as women in
both arms were administered with this preventative tool. The same applies for CTX in Trial on HIV-positive
women. IPTp-placebo in Trial on HIV-positive women was considered as “doing nothing” option with no costs
associated. Incremental net costs were calculated, which included the incremental costs of the intervention
minus treatment savings due to its efficacy.
doi:10.1371/journal.pone.0125072.g001
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primary endpoint (prevalence of peripheral maternal malaria infection at delivery) was signifi-
cantly lower in women receiving IPTp-MQ compared to those receiving IPTp-placebo (Risk
Ratio 0.47 (95%CI 0.27; 0.82); p = 0.008). However, this was an intermediate outcome with
lower direct public health relevance compared to other trial outcomes such as morbidity [27].
Accordingly, the outcomes included were the incidence of clinical malaria and maternal anae-
mia at delivery (Hb<11 g/dl)(both lower in the MQ group compared with the SP group
(Table 1)) in the trial in HIV-negative women, and the incidence of non-obstetric hospital ad-
missions (lower in the MQ group compared with the placebo group (Table 2)) in the trial in
HIV-positive women. These health outcomes were translated into disability adjusted life years
(DALYs) using the parameters shown in Tables 1 and 2.
Dizziness and vomiting were the most frequent tolerability adverse events related to medica-
tion being significantly higher in the MQ groups of both trials. Approximately 35% of the
study women experienced either transient dizziness or vomiting in the MQ groups compared
with 10% in the comparator groups. However, only about 25% of these adverse events were
moderate and less than 5% severe and likely to interfere with normal daily life activities. Low
tolerability was translated into household indirect costs.
Disability adjusted life years
For both trials, the number of episodes averted for a target of 1000 women receiving IPTp was
defined as the protective efficacy (1-RR) times the incidence of the episodes (person-year at
risk) in the comparator group, times 1000, in the two trials. The number of deaths averted was
obtained by multiplying the number of episodes averted by the case fatality ratio, specific to
pregnant women where data were available [29–32]. DALYs averted were calculated by multi-
plying the number of DALYs due to the disease by the reduction in morbidity and mortality re-
sulting from the intervention. DALYs were discounted but not age-weighted [33]. For the trial
in HIV-negative women, total DALYs averted were the sum of DALYs averted for clinical ma-
laria and for anaemia. For the trial in HIV-positive women, total DALYs averted were the sum
of DALYs averted for each of the three categories of non-obstetric hospital admission (moder-
ate abdominopelvic problems; infectious diseases (acute severe episode); and severe anaemia
(Hb<7 g/dl)) (Table 2).
Cost savings
Health system and household cost savings were calculated by multiplying inpatient and outpa-
tient treatment costs by the number of admissions and outpatient episodes averted, respective-
ly. For the trial in HIV-negative pregnant women, both health system and household costs for
an outpatient visit and for an admission due to malaria were estimated based on data from
Tanzania and Mozambique [29]. In Tanzania, an ad hoc exit survey was undertaken among
225 pregnant or post-postpartum women with malaria (71 were inpatients and 154 outpa-
tients) [34]. Health system costs were extrapolated to the remaining countries based on the ra-
tios between WHO-Choice outpatient and inpatient costs of Benin and Gabon and the average
previously estimated costs of Mozambique and Tanzania [35]. For example, health system
costs of Benin were estimated by multiplying the average health system costs of Mozambique
and Tanzania by the ratio between the average WHO-Choice costs of Mozambique and Tanza-
nia and WHO-Choice costs of Benin. Using the same approach, the average household costs
fromMozambique and Tanzania for malaria treatment were extrapolated to Benin and Gabon
based on the estimates of a previous study [36]. Inpatient malaria episodes averted were the
total number of malaria episodes averted times the proportion of malaria cases hospitalized
[37]. Outpatient malaria episodes averted were the result of the total number of malaria
Economic Evaluation of an Alternative Drug as IPTp
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Table 1. Input variables of the threshold and cost-effectiveness analyses of IPTp-MQ compared with IPTp-SP in HIV-negative pregnant women.
Values
(range/CI95%)
Distribution Estimated
parameters
Source
Costs estimate
Time nurses take to provide 1 dose Sulfadoxine-Pyrimethamine (SP);
minutes
2.5 Triangular
symmetric
Min = 2; Max = 3 Self reported by
nurses
Time nurses take to provide 1 dose Meﬂoquine (MQ); minutes 5.5 Triangular
symmetric
Min = 5; Max = 6 Self reported by
nurses
Nurses' monthly cost of labour; average including Gabon (US$) 413.25 Gamma α = 11.52; β =
35.87
Country MoH
Nurses' monthly cost of labour; average excluding Gabon (US$) 336.73 Gamma α = 283.47; β =
1.19
Country MoH
MQ (250mg) price per tablet (US$) 0.5 Triangular
asymmetric
Min = 0.46;
Max = 0.90
(MMV + GF)*
International SP (500 mg + 25 mg) price per tablet (US$) 0.07 Lognormal μ = -2.66; σ =
0.04
GF**
Average number of tablets per dose MQ—includes drug wastage 3.75 Point estimate - [20, 21]
Average number of tablets per dose SP—includes drug wastage 3.15 Point estimate - Trial data
Disability-Adjusted Life Years (DALYs) estimate (not age-weighted)
Discount rate 0.03 Point estimate - Assumption
Average women's age (years) 24.5 Point estimate [20]
Length Disability—malaria (years) 0.01(0.005–
0.02)
Gamma α = 9.89; β =
0.001
Experts opinion
Length Disability—anaemia malaria related (years) 0.06 (0.04–
0.11)
Gamma α = 8.31; β =
0.007
[71]
Across country average life expectancy of women aged 24.5 years (in
years, for the year 2011)—including Gabon
46.51 Point estimate - [72]
Across country average life expectancy of women aged 24.5 years (in
years, for the year 2011)—excluding Gabon
45.63 Point estimate - [72]
Sensitivity analysis: life expectancy of Japanese women aged 24.5 (in
years, for the year 2011)
66.28 Point estimate - [72]
Disability weight (moderate anaemia) 0.058 (0.04–
0.09)
Lognormal μ = -2.85; σ =
0.21
[73]
Disability weight (infectious disease: acute episode, severe) 0.21 (0.14–
0.30)
Lognormal μ = -1.56; σ =
0.19
[73]
DALYs averted estimate
Incidence of clinical malaria SP arm (episodes per PYAR) 0.17 Point estimate - [20]
Clinical malaria Relative Risk MQ arm—First or only episode. [Incidence
(Episodes person/year) in the SP group = 0.17; incidence in the MQ
group = 0.12]
0.67 (0.52–
0.88)
Lognormal μ = -0.42; σ =
0.14
[20]
Anaemia at delivery (Hb<11 g/dl) Relative Risk MQ arm [Prevalence in the
SP group = 44.1; prevalence in the MQ group = 40.5]
0.92 (0.85–
0.99)
Lognormal μ = -0.08; σ =
0.04
[20]
Case fatality ratio malaria % 0.33 (0.26–
0.45)
Beta α = 3.91; β =
1182.49
[29]
Case fatality ratio anaemia % 1 Beta α = 98.99; β =
9800.01
[30]
Adherence to intervention
Drop out rate ﬁrst dose MQ % 2 Beta α = 97.98; β =
4801.02
[20]
Drop out rate second dose MQ % 14 Beta α = 85.86; β =
527.43
[20]
Drop out rate ﬁrst dose SP % 1 Beta α = 98.99; β =
9800.01
[20]
(Continued)
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episodes averted times the percentage of presumptive malaria in pregnancy cases seeking care
at public health facilities [29]. It was assumed that anaemia was not the cause of either outpa-
tient visits or hospital admissions [38]. Therefore, no treatment savings were associated with
this outcome.
In the trial in HIV-positive pregnant women, savings were based on the number of non-ob-
stetric admissions averted in the three categories. Health system admission costs averted in
Mozambique and Tanzania were represented by the malaria treatment figures used for the trial
in HIV-negative pregnant women, while estimates from a published study were used for Kenya
[39]. Admission costs averted for the households were the same as for the trial in HIV-negative
pregnant women in the case of Mozambique and Tanzania [29, 34] and estimated from a
Table 1. (Continued)
Values
(range/CI95%)
Distribution Estimated
parameters
Source
Drop out rate second dose SP % 8 Beta α = 91.92; β =
1057.08
[20]
Savings due to the efﬁcacy of IPTp-MQ compared with IPTp-SP
% of malaria cases seeking care 50 Triangular
symmetric
Min = 40;
Max = 60
[29]
% of malaria cases in pregnancy that are severe 6 Point estimate - [20]
With the inclusion of Gabon:
Health system inpatient savings per malaria episode (US$) 188.68 Gamma α = 2.14; β =
88.06
Our estimate
Health system outpatient savings per malaria episode (US$) 11.61 Gamma α = 5.01; β =
2.31
Our estimate
Households’ outpatient direct treatment savings per malaria episode (US$) 13.47 Gamma α = 0.14; β =
93.39
Our estimate
Households’ outpatient indirect treatment savings per malaria episode (US
$)
1.58 Gamma α = 0.16; β =
9.62
Our estimate
Households’ inpatient direct treatment savings per malaria episode (US$) 89.15 Gamma α = 0.43; β =
204.60
Our estimate
Households’ inpatient indirect treatment savings per malaria episode (US$) 2.69 Gamma α = 0.12; β =
22.07
Our estimate
With the exclusion of Gabon:
Health system inpatient savings per malaria episode (US$) 40.65 Gamma α = 100; β = 0.41 Our estimate
Health system outpatient savings per malaria episode (US$) 4.32 Gamma α = 100; β = 0.04 Our estimate
Households’ outpatient direct treatment savings per malaria episode (US$) 2.16 Gamma α = 0.16; β =
13.74
Our estimate
Households’ outpatient indirect treatment savings per malaria episode (US
$)
0.8 Gamma α = 0.17; β =
4.65
Our estimate
Households’ inpatient direct treatment savings per malaria episode (US$) 20.97 Gamma α = 0.56; β =
37.32
Our estimate
Households’ inpatient indirect treatment savings per malaria episode (US$) 1.75 Gamma α = 0.13; β =
13.63
Our estimate
All monetary values are expressed in US$ 2012
IPTp = Intermittent Preventive Treatment of malaria in pregnancy; HIV = Human Immunodeﬁciency Virus
MQ = Meﬂoquine; SP = Sulphadoxine-Phyrimethamine; PYAR = Person-year at risk; RR = Relative Risk.
α, β are the parameters of the Beta and Gamma distributions and μ, σ are the parameters of the lognormal distribution.
*Medicine for malaria venture price under negotiation and ranges given by lowest and highest Global Fund procurement prices.
**The average Global Fund procurement price for SP in Sub-Saharan Africa for the year 2012.
doi:10.1371/journal.pone.0125072.t001
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Table 2. Input variables of the threshold and cost-effectiveness analyses of IPTp-MQ compared with IPTp-placebo in HIV-positive pregnant
women.
Values
(range/CI
95%)
Distribution Estimated
Parameters
Source
Costs estimate
Time nurses take to provide 1 dose MQ (minutes) 5.5 Triangular
symmetric
Min = 5; Max = 6 Self reported by
nurses
Nurses' monthly cost of labour (US$) 332.17 Gamma α = 205.95; β =
1.61
Country MoH
MQ (250 mg) price per tablet (US$) 0.51 Triangular
asymmetric
Min = 0.46;
Max = 0.9
MMV + GF*
Average number of tablets per dose MQ—includes drug wastage 3.75 Point estimate - [21]
Disability-Adjusted Life Years (DALYs) estimate
Discount rate 0.03 Point estimate - Assumption
Incidence of all cause admissions placebo arm (episodes per PYAR) 0.35 Point estimate - [21]
Non-obstetric hospital admissions Relative Risk MQ arm [Incidence
(episodes per person/year) placebo group = 0.35; incidence MQ
group = 0.20]
0.59 (0.37–
0.95)
Lognormal μ = -0.49; σ =
0.24
[21]
Across country average Life Expectancy of women aged 26.5 years (in
years, for the year 2011)
44.06 Point estimate - [72]
Sensitivity analysis: Life Expectancy of Japanese women aged 26.5 (in
years, for the year 2011)
61.38 Point estimate - [72]
Disability weights infectious diseases (acute severe episode) 0.21 (0.14–
0.29)
Lognormal μ = -1.56; σ =
0.19
[73]
Disability weights moderate abdominopelvic problem 0.12 (0.08–
0.18)
Lognormal μ = -2.09; σ =
0.19
[73]
Disability weights severe anaemia 0.164 (0.11–
0.23)
Lognormal μ = -1.81; σ =
0.18
[73]
Length disability 0.0273 Gamma μ = 100; σ =
0.0003
DALYs averted estimate
Case fatality ratio HIV positive adults with all cause co-morbidity % 35 Beta α = 64.65; β =
120.06
[31]
Case fatality ratio severe anaemia % 1.4 Beta α = 1.03; β =
72.60
[30]
Case fatality ratio maternal disorders % 3.4 Beta α = 96.57; β =
2,743.61
[32]
Adherence to intervention
Drop out rate ﬁrst dose MQ % 2 Beta α = 97.98; β =
4,801.02
[21]
Drop out rate second dose MQ % 10 Beta α = 89.9; β =
809.10
[21]
Drop out rate third dose MQ % 19 Beta α = 80.81; β =
344.50
[21]
Savings due to the efﬁcacy of IPTp-MQ compared with IPTp-SP
Health system savings (US$)
Health system inpatient savings per hospitalisation episode (US$) 28.48 Gamma α = 6.48; β =
4.39
Our estimate
Households’ inpatient treatment savings (US$)
Direct 10.92 Gamma α = 6.48; β =
4.39
Our estimate
(Continued)
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cross-sectional study recently conducted among pregnant women with malaria in the case of
Kenya (Hill, J and Webster, J, unpublished data).
For both trials, household cost savings were split into direct and indirect. Direct savings re-
ferred to medical (e.g. drugs, diagnostics) and non-medical (e.g. transportation) costs averted
due to fewer malaria episodes and non-obstetric admissions. Indirect cost savings had two
components, the aversion of time lost due to malaria and to non-obstetric admissions and the
additional time lost (one day on average) due to poor MQ tolerability. Time was valued at the
national minimum salary in force, averaged across countries [40]. All costs were expressed in
US$ 2012 and discounted at 3%.
Intervention costs
Costs associated with IPTp-MQ or with IPTp-SP were estimated as the drug cost plus the value
of the health personnel time taken to administer the intervention. Time taken to administer
one dose of MQ was reported by the health personnel involved in the trials. Time taken to ad-
minister one dose of SP was obtained from a previous study [29]. In the trial in HIV-negative
women, incremental costs were calculated as the difference between the time needed to provide
MQ and SP multiplied by the value of health personnel time plus the difference between unit
cost of drugs (price per tablet) multiplied by the number of tablets administered. The value of
health personnel time was the average salary across sites. In the trial in HIV-positive women,
IPTp-placebo was considered as a “do-nothing” option with no associated costs, thus the incre-
mental costs were health personnel time to provide three doses of MQmultiplied by the value
of their time plus the cost of MQ. Mefloquine tablets of 250 mg were administered in both trials
at a dosage of 15 mg/kg. Thus, the number of tablets of MQ per dose was calculated based on
women’s median weight at the first IPTp administration. The number of tablets of SP was fixed
at three per dose (each tablet containing 500 mg sulfadoxine and 25 mg pyrimethamine) [10].
The price of SP was estimated using the average Global Fund procurement price in Sub-Saha-
ran Africa for the year 2012, augmented by 10% to account for insurance and freight, and by
an additional 15% to include local transportation costs, leading to a cost of US$ 0.07 per tablet.
The average international market price of MQ for the year 2012 (including insurance, ship-
ment and local transportation), was nearly 1 US$ per tablet [41]. Despite being present in the
private market of some sub-Saharan African countries for many years [42], widespread use of
MQ as mono-therapy has never occurred for either malaria prevention or treatment in Africa.
For this reason, there is not a large scale programme price for MQ in the region and for the
purpose of this study. Its average price was estimated by doubling the active pharmaceutical in-
gredient price of 800 US$/kilogram to include formulation and packing costs and by adding
Table 2. (Continued)
Values
(range/CI
95%)
Distribution Estimated
Parameters
Source
Indirect 5.34 Gamma α = 6.48; β =
4.39
Our estimate
All monetary values are expressed in US$ 2012
IPTp = Intermittent Preventive Treatment of malaria in pregnancy; HIV = Human Immunodeﬁciency Virus
MQ = Meﬂoquine; SP = Sulphadoxine-Phyrimethamine; PYAR = Person-year at risk; RR = Relative Risk.
α, β are the parameters of the Beta and Gamma distributions and μ, σ are the parameters of the lognormal distribution.
*Medicine for malaria venture price under negotiation and ranges given by lowest and highest Global Fund procurement prices.
doi:10.1371/journal.pone.0125072.t002
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10% for freight and insurance and 15% for local transportation costs [43]. This gave a mean
MQ price of US$ 0.50 per tablet. To allow for uncertainty the minimum and maximum Global
Fund procurement price of MQ in Asia, where MQ is used in public health programmes, were
used as the range [44].
Intervention costs were calculated for 1000 pregnant women receiving IPTp. Trial attrition
was considered in cost calculation by reducing the number of doses at each administration re-
sulting from all-cause women’s drop-out. Input values are presented in Table 1 for the trial in
HIV-negative pregnant women and in Table 2 for the trial in HIV-positive pregnant women.
Cost effectiveness analyses
The health system perspective was used for the net incremental cost-effectiveness ratios
(ICERs) calculation. ICERs were defined as net as health system cost savings were subtracted
from the incremental costs of the intervention. Net ICERs were equal to:
Trial in HIVnegative pregnant women¼
Costs associated with IPTpMQ Costs associated with IPTpSPHealth system savings
DALYs averted clinical malaria þ DALYs averted anaemia
Trial in HIVpositive pregnant women¼
Costs associated with IPTpMQHealth system savings
DALYs averted nonobstetric hospital admissions
The maximum level at which IPTp-MQ is cost-effective compared with IPTp-SP (trial in
HIV-negative pregnant women) or with the “do-nothing” alternative (trial in HIV-positive
pregnant women) was deﬁned by setting a conservative net incremental cost-effectiveness
threshold of 240 US$ per DALY averted [45]. This value corresponds to the threshold below
which an intervention is considered cost-effective, proposed by the World Bank in 1993 up-
dated to 2012 prices [46].
Being the country with the highest GDP per capita, Gabon also had higher health worker
salaries and health system costs compared with the other countries, with a substantial impact
on the numerator of the ICER [24]. Cost-effectiveness results were, therefore presented in two
scenarios, including and excluding Gabon, respectively.
Management of uncertainty
All model inputs were expressed as probability distributions (Tables 1 and 2) [47]. Distribution
parameters were calculated based on mean values and lower and upper range values. Where
lower and upper range values were unknown, a standard deviation of 20% was assumed and
distribution parameters were estimated accordingly. Finally, parameters were fitted through
maximum likelihood for those variables for which patient or country level data were available,
such as household and health system costs. Stata 12.1 (Stata Corporation, College Station, TX,
USA) was used to calculate these estimates. Probabilistic sensitivity analysis was performed
through Monte Carlo simulations using Microsoft Excel. The cumulative average net monetary
benefits (threshold levelincremental effects—incremental costs) were depicted in graphs to
evaluate the number of iterations needed to produce stable results. One-way sensitivity analysis
was undertaken on life expectancy by changing local values, used in the base scenario, to the
life expectancy of Japanese women, globally the longest living. A threshold analysis of the cost-
effectiveness of IPTp-MQ was performed to estimate cut-off points beyond which the
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intervention is no longer cost-effective. Threshold analysis was performed on the MQ price for
both trials and on the SP price, malaria incidence, and on protective efficacy against clinical
malaria for the trial in HIV-negative pregnant women.
ICERs were presented graphically in the cost-effectiveness plane [48] and as acceptability
curves [49, 50]. The cost-effectiveness plane plots all Monte Carlo simulations produced with
respect to DALYs averted (X axis) and incremental costs (Y axis), allowing the visualization of
the confidence area delimited by the 95% confidence ellipses. Acceptability curves show the
probability that IPTp-MQ is cost-effective (Y axis) according to the different levels of policy-
maker willingness to pay for each DALY averted (X axis).
Results
In the trial in HIV-negative pregnant women, for 500 women receiving IPTp-MQ in compari-
son with 500 receiving IPTp-SP, the number of DALYs averted from malaria and anaemia re-
duction was 9.23 (CI95% 9.09; 9.38) (Table 3). When Gabon was included in the analysis, the
incremental cost of delivering two doses of MQ for IPTp was US$ 2,007.21 (CI95% 1,992.48;
2,021.93). Health system savings were US$ 949.10 (CI95% 925.29; 972.91), leading to a net in-
cremental cost of US$ 1,058.11 (CI95% 1,030.16; 1,086.05). The net ICER was US$ 136.30
(CI95% 131.41; 141.18) per DALY averted. Household direct cost savings were US$ 668.97
(CI95% 619.13; 718.81) while indirect cost savings were negative (i.e. were a net cost) estimated
at US$ -44.23 (CI95% -49.58; -38.87). When Gabon was excluded, incremental cost was slightly
reduced but health system savings were almost four times lower yielding a net ICER of US$
237.78 (CI95% 230.99; 244.57). Household direct and indirect cost savings decreased by 80%
and 15%, respectively, compared with the inclusion of Gabon.
In the trial in HIV-positive women, the cost of delivering 3 doses of IPTp-MQ to 1,000
women was US$ 6,667.86 (CI95% 6,625.15; 6,710.56) (Table 4). The number of DALYs averted
was 603.33 (CI95% 592.94; 613.72) based on 138.91 (CI95% 136.60; 141.22) non-obstetric ad-
missions averted and on 24.57 (CI95% 24.15; 24.99) deaths averted. Health system savings
were nearly US$ 4,000 leading to an incremental net cost of US$ 2,712.96 (CI95% 2,658.30;
2,767.62). The net cost per DALY averted was US$ 6.96 (CI95% 4.22; 9.70). Household direct
and indirect savings were US$ 1,519.10 (CI95% 1,470.34; 1,567.86) and US$ 543.90 (CI95%
530.64; 557.16), respectively.
Approximately 1,600 random iterations of the cost-effectiveness model were required to
achieve stable results from the two models (with and without Gabon) of the trial in HIV-nega-
tive pregnant women S1 Fig Stable results were achieved in the trial in HIV-positive women
(S2 Fig) at about 1,800 iterations. With 2,000 iterations the results in the three models can be
considered robust.
Figs 2–4 show the cost-effectiveness planes. In all the figures the average simulation points
are situated below and to the right of the threshold limit indicating that, on average, IPTp-MQ
was more cost-effective than the comparators. However, in Fig 2 (trial in HIV-negative
women, Gabon included) a fraction of the confidence area lies above and to the left of the
threshold limit. Several simulated combinations of incremental costs and health effects ex-
ceeded US$ 240 per DALY averted indicating that IPTp-MQ is not cost-effective when the in-
cremental costs are higher than approximately US$ 1,000 and fewer than 8 DALYs are averted.
In Fig 3, (trial in HIV-negative women, Gabon excluded) the share of the confidence area lying
above/left of the threshold limit is larger, defining a wider non-cost-effective region. For the
trial in HIV-positive women the entire confidence area lies below the threshold limit, assessing
that the intervention is cost-effective across all possible combinations of intervention costs and
health effects (Fig 4).
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The acceptability curves for the trial in HIV-negative women are shown in Fig 5. At each
level of theoretical willingness to pay (X-axis) the probability that the intervention is cost-effec-
tive (Y-axis) is much higher when Gabon is included in the analysis (red line) than when it is
excluded (blue line). To achieve a 90% probability that the intervention is cost-effective policy
makers should be willing to pay around 270 US$ per DALY averted (Gabon included) or US$
380 (Gabon excluded). For the trial in HIV-positive women a willingness to pay of US$ 20 per
DALY averted would achieve a 90% probability that the intervention is cost-effective (Fig 6).
Cost-effectiveness results did not change considerably when the life expectancy of Japanese
women was used to calculate DALYs averted. For the trial in HIV-negative women, the num-
ber of DALYs averted increased to 10.32 (CI95% 10.07; 10.57) and to 9.60 (CI95% 9.38; 9.82)
Gabon included or excluded, respectively; while the net ICER decreased to US$ 133.60 (CI95%
117.47; 149.73) and US$ 213.71 (CI95% 202.85; 224.57). For the trial in HIV-positive women,
the number of DALYs averted increased to 695.58 (CI95% 676.68; 714.48) and the net ICER
fell to US$ 6.26 (CI95% 3.55; 8.97).
Table 3. HIV-negative trial: Results of cost-effectiveness analysis (per 1000 pregnant HIV-negative
women).
Value (CI 95%)
Health impact of IPTp-MQ on malaria and anaemia
Number of maternal clinical malaria episodes averted 55.14 (54.47; 55.81)
Number of maternal anaemia at delivery cases averted 13.39 (13.12; 13.66)
Number of malaria admissions averted 3.31 (3.27; 3.35)
Number of malaria outpatient visits averted 27.14 (27.14; 27.83)
Number of malaria deaths averted 0.18 (0.178; 0.183)
Number of anaemia deaths averted 0.13 (0.131; 0.136)
Number of DALYs averted (malaria + anaemia) 9.23 (9.09; 9.38)
Cost-effectiveness (including Gabon)
Incremental costs (IPTp-MQ—IPTp-SP) (US$) 2,007.21 (1,992.48; 2,021.93)
Health system treatment savings (US$) 949.10 (925.29; 972.91)
Incremental net costs* (US$) 1,058.11 (1,030.16; 1,086.05)
Net incremental costs per DALY averted** (US$) 136.30 (131.41; 141.18)
Treatment household savings due to IPTp-MQ efﬁcacy on clinical malaria (including Gabon)
Households direct treatment savings (US$) 668.97 (619.13; 718.81)
Households indirect treatment savings (US$) -44.23 (-49.58; -38.87)
Cost-effectiveness (excluding Gabon)
Incremental costs (IPTp-MQ—IPTp-SP) (US$) 1,992.02 (1,977.42; 2,006.63)
Health system treatment savings (US$) 254.61 (251.33; 257.89)
Incremental net costs* (US$) 1,737.41 (1,722.42; 1,752.41)
Net incremental costs per DALY averted** (US$) 237.78 (230.99; 244.57)
Treatment household savings due to IPTp-MQ efﬁcacy on clinical malaria (excluding Gabon)
Households direct treatment savings (US$) 128.29 (120.01; 136.56)
Households indirect treatment savings (US$) -51.74(-54.49; -48.99)
All monetary values are expressed in US$ 2012
IPTp = Intermittent Preventive Treatment of malaria in pregnancy; HIV = Human Immunodeﬁciency Virus
MQ = Meﬂoquine; SP = Sulphadoxine-Phyrimethamine; DALY = Disability-adjusted Life Year.
*Incremental net costs are equal Incremental cost minus Health system treatment savings
**Net incremental costs per DALY averted are equal Incremental net costs divided by number of
DALYs averted
doi:10.1371/journal.pone.0125072.t003
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According to the probabilistic threshold analysis (Fig 7) for the trial in HIV-negative
women (Gabon included), IPTp-MQ was no longer cost-effective compared with IPTp-SP
when: the price of MQ was over US$ 0.87 per tablet; the price of SP was less than US$ 0.001 per
tablet; the incidence of clinical malaria was less than 0.12 episodes per person-year at risk and
the RR was over 0.81. Modest shifts of all the variables were allowed for IPTp-MQ to remain
cost-effective with the exclusion of Gabon. For the trial in HIV-positive women, IPTp-MQ
compared with IPTp-placebo was no longer cost-effective when the MQ price per tablet was
higher than US$ 10.7 per tablet.
Discussion
This economic evaluation found that at an estimated price of 0.50 US$ per tablet the addition
of an effective antimalarial as IPTp is highly cost-effective in HIV-positive pregnant women re-
ceiving daily CTXp and in the context of LLINs. Moreover, this addition would bring modest
household cost savings (on average about 2 US$ per pregnant woman) and would remain cost-
effective up to a price of over 10 US$ per tablet of the antimalarial drug. In HIV-negative preg-
nant women a more effective antimalarial drug than SP may be considered as a cost-effective
alternative for IPTp at the price of 0.50 US$ per tablet and up to US$ 0.80 per tablet.
IPTp with MQ was found highly cost-effective in HIV-positive women because of the large
number of DALYs averted as a consequence of reducing non-obstetric admissions. In this trial
in HIV-positive women, the reduction in non-obstetric admissions, mainly caused by infec-
tions, was consistent with a decrease in the incidence of morbidity outcomes both malaria-re-
lated and overall [51–54]. Moreover, malaria is known to cause immunosuppression, leading
to increased risk and severity of other infections [55, 56]. As it has been shown in children in
previous antimalarial drug trials, it is plausible that the decreased risk of malaria infection in
Table 4. HIV-positive trial: Results of the cost-effectiveness analysis (per 1000 pregnant HIV-positive
women).
Value (CI 95%)
Health impact of IPTp-MQ
Number of non-obstetric admissions averted 138.91 (136.60; 141.22)
Number of deaths averted 24.57 (24.15; 24.99)
Number of DALYs averted 603.33 (592.94; 613.72)
Cost-effectiveness
Costs associated with IPTp-MQ (US$) 6,667.86 (6.625.15; 6,710.56)
Health system treatment savings (US$) 3,954.90 (3,854.54; 4,055.26)
Incremental net cost* (US$) 2,712.96 (2,658.30; 2,767.62)
Net incremental costs per DALY averted** (US$) 6.96 (4.22; 9.70)
Treatment savings due to IPTp-MQ efﬁcacy on clinical malaria
Households direct savings (US$) 1,519.10 (1,470.34; 1,567.86)
Households indirect savings (US$) 543.90 (530.64; 557.16)
All monetary values are expressed in US$ 2012
IPTp = Intermittent Preventive Treatment of malaria in pregnancy; HIV = Human Immunodeﬁciency Virus
MQ = Meﬂoquine; SP = Sulphadoxine-Phyrimethamine; DALY = Disability-adjusted Life Year.
*Incremental net costs are equal to Costs associated with IPTp-MQ minus Health system
treatment savings
**Net incremental costs per DALY averted are equal to Incremental net costs divided by Number of
DALYs averted
doi:10.1371/journal.pone.0125072.t004
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the women who received MQ had an impact in reducing the incidence and/or severity of other
infections [57].
Among HIV-negative pregnant women although the absolute differences between interven-
tion groups in the outcomes were small (episodes person/year 0.17 and 0.12 in the SP and MQ
group, respectively), IPTp with MQ was cost-effective mainly due to the economic impact on
the reduction in the incidence of clinical malaria episodes and, therefore, on the health system
costs of care seeking among pregnant women.
Although the two clinical trials this study is based on, have discarded MQ at the dose of
15mg/kg as the drug suitable for substituting SP or to integrating CTXp, they have shown
the health benefits of using a more efficacious antimalarial than SP for HIV-negative, and of
adding an efficacious antimalarial to daily CTXp for HIV-positive pregnant women. These
findings were considered as notable and the cost-effectiveness analysis of an alternative anti-
malarial was modelled taking findings on MQ as an example. Importantly, while the need of an
alternative antimalarial to SP for IPTp is very much recognized among the public health com-
munity, MQ is, up to now, the only one potential alternative option.
The choice of the outcomes used in this economic analysis was based on their public health
impact as well as the statistically significant difference found between intervention groups. In-
termediate health outcomes are generally used in economic evaluations when final health ones
have not been measured [58]. However, final health outcomes are preferred when available
from the study [25, 59]. In this case, although malaria parasitemia and placental infection were
significantly reduced in the IPTp-MQ group, the use of a clinical outcome such as hospital
Fig 2. Cost effectiveness plane: IPTp-MQ versus IPTp-SP in HIV-negative pregnant women in Benin,
Gabon, Mozambique and Tanzania. IPTp-MQ = Intermittent Preventive Treatment of malaria in pregnancy
with Mefloquine; IPTp-SP = Intermittent Preventive Treatment of malaria in pregnancy with Sulphadoxine-
Phyrimethamine; HIV = Human Immunodeficiency Virus; DALYs = Disability-adjusted life years. The graph
plots 2,000 Monte Carlo simulations of the incremental cost-effectiveness ratio (ICER) with respect to its
components: health impact (X-axis) and incremental costs (Y-axis). Average simulation point, ellipse of
confidence (95%) and threshold level of the ICER (240 US$/DALY averted) are also depicted. Cost-effective
dots are placed below/right the threshold line.
doi:10.1371/journal.pone.0125072.g002
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admissions avoids making an hypothetical extrapolation of the parasitological outcome to one
of public health relevance, leading to more direct and therefore, realistic estimates [29].
In the trial in HIV-negative women, the ICER resulting from the exclusion of Gabon was
nearly twice the one resulting from its inclusion. Since the same drug costs were used across all
settings, costs were largely driven by the higher cost of health personnel and other health ser-
vice costs in Gabon, which led to higher health system savings arising from the reduction in
the number of malaria cases. In practice, different prices may be applied in different countries
due to market segmentation by pharmaceutical companies [60]; on the other hand, pooled pro-
curement arrangements will tend to lead to price convergence. Assuming a common drug
price, the implementation of a more efficacious malaria prevention tool in pregnancy will be
more cost-effective, everything else constant, in settings where treatment cost is higher. How-
ever, from a public health perspective, the implementation of efficacious prevention is equally
needed in any setting where the burden of disease is high and where it consumes a considerable
share of health system resources [61].
This study differs from existing economic evaluations of IPTp in a number of aspects. First,
we use a hypothetical price for MQ, since it is not currently procured in large quantities for
public health programmes, while in previous economic evaluations of IPTp the price of the
medicine was either known or not relevant to the study objectives [29, 62–67]. Second, the trial
in HIV-negative women was the first economic evaluation comparing a different drug for IPTp
instead of comparing the currently recommended IPTp-SP with “do-nothing”. Third, there are
several differences between the current study and the only economic evaluation model that
Fig 3. Cost effectiveness plane: IPTp-MQ versus IPTp-SP in HIV-negative pregnant women in Benin,
Mozambique and Tanzania. IPTp-MQ = Intermittent Preventive Treatment of malaria in pregnancy with
Mefloquine; IPTp-SP = Intermittent Preventive Treatment of malaria in pregnancy with Sulphadoxine-
Phyrimethamine; HIV = Human Immunodeficiency Virus; DALYs = Disability-adjusted life years. The graph
plots N = 2,000 Monte Carlo simulations of the incremental cost-effectiveness ratio (ICER) with respect to its
components: health impact (X-axis) and incremental costs (Y-axis). Average simulation point, ellipse of
confidence (95%) and threshold level of the ICER (240 US$/DALY averted) are also depicted. Cost-effective
dots are placed below/right the threshold line.
doi:10.1371/journal.pone.0125072.g003
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Fig 4. Cost effectiveness plane: IPTp-MQ versus IPTp-Placebo in HIV-positive pregnant women in
Kenya, Mozambique and Tanzania. IPTp-MQ = Intermittent Preventive Treatment of malaria in pregnancy
with Mefloquine; HIV = Human Immunodeficiency Virus; DALYs = Disability-adjusted life years. The graph
plots 2,000 Monte Carlo simulations of the incremental cost-effectiveness ratio (ICER) with respect to its
components: health impact (X-axis) and incremental costs (Y-axis). Average simulation point, ellipse of
confidence (95%) and threshold level of the ICER (240 US$/DALY averted) are also depicted.
doi:10.1371/journal.pone.0125072.g004
Fig 5. Cost-effectiveness of IPTp-MQ versus IPTp-SP in HIV-negative pregnant women in Benin,
Gabon, Mozambique and Tanzania: acceptability curves. IPTp-MQ = Intermittent Preventive Treatment of
malaria in pregnancy with Mefloquine; IPTp-SP = Intermittent Preventive Treatment of malaria in pregnancy
with Sulphadoxine-Phyrimethamine; HIV = Human Immunodeficiency Virus; DALYs = Disability-adjusted life
years. Acceptability curves were constructed by plotting the cumulative distribution of the incremental cost-
effectiveness ratios (ICERs) of IPTp-MQ compared with IPTp-SP per DALYs averted. The Y axis is
interpreted as probability that the intervention is cost-effective for every level of policy makers’ willingness to
pay for each DALY averted (X axis). US$ 136.30 per DALY averted (CI95% 131.41–141.18) is the ICER for
the scenario including Benin, Gabon, Mozambique and Tanzania. US$ 237.99 (CI95% 230.99–244.57) per
DALY averted is the ICER for the scenario excluding Gabon.
doi:10.1371/journal.pone.0125072.g005
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differentiated the impact of IPTp-SP by HIV status [64]. The latter mentioned model included
both HIV-positive and negative pregnant women, while the current study estimates two sepa-
rate models for the two groups of women. The health effect of IPTp-SP was represented by the
reduction in placental parasitemia modeled to estimate the number of low birth weight cases
averted, while the present study uses more direct health outcomes as in a previous study [29].
In addition, the previous study took place before the introduction of daily CTXp, while the cur-
rent study estimates the cost-effectiveness of the introduction of an antimalarial for IPTp in ad-
dition to CTXp [68].
The choice of the values of parameters used to calculate DALYs has an impact on cost-effec-
tiveness results [69]. In this study, country specific, instead of international life expectancies
were used to provide local policy makers with useful information in their decision making pro-
cess. However, results of this evaluation did not dramatically change even when the highest
possible life expectancy level, the one of Japanese women, was used.
For HIV-positive women, the value of the loss of ability to work caused by the low tolerabili-
ty to MQ in approximately 30% of trial participants, reduced indirect cost savings arising from
the efficacy of the drug. For HIV-negative women, indirect cost savings were outweighed by
the value of the reduced ability to work, translating savings into an indirect cost for the house-
holds. The economic value of low tolerability could be seen as a transfer of costs from the
health system to pregnant women and ultimately to the whole community [70].
Safety concerns on MTCT of HIV were not taken into account in this economic evaluation
for several reasons: they did not constitute study outcomes; they were found in an exploratory
analysis of trial data; and the present study aimed at modelling the cost-effectiveness of an
Fig 6. Cost-effectiveness of IPTp-MQ versus IPTp-Placebo in HIV-positive pregnant women in Kenya,
Mozambique and Tanzania: acceptability curve. IPTp-MQ = Intermittent Preventive Treatment of malaria
in pregnancy with Mefloquine; HIV = Human Immunodeficiency Virus; DALYs = Disability-adjusted life years.
The acceptability curve was constructed by plotting the cumulative distribution of the incremental cost-
effectiveness ratio (ICER) of IPTp-MQ compared with IPTp-Placebo per DALYs averted. The Y axis is
interpreted as probability that the intervention is cost-effective for every level of policy makers’ willingness to
pay for each DALY averted (X axis). US$ 6.96 per DALY averted (CI95% 4.22–9.70) is the ICER resulting
from the analysis.
doi:10.1371/journal.pone.0125072.g006
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alternative drug for IPTp which will have to be safe, with no need, therefore, to consider
such concerns.
In conclusion, adding IPTp with an effective antimalarial to daily CTXp in HIV-positive
pregnant women is highly cost-effective. Moreover, IPTp with an efficacious alternative anti-
malarial is more cost-effective than IPTp-SP in HIV-negative pregnant women. However, the
potential utility of MQ (15 mg/kg) for IPTp was compromised by low tolerability in both trials
and the safety concerns in HIV-positive women. Therefore, further research is needed to find
an alternative antimalarial to eventually replace SP for the prevention of malaria in HIV-nega-
tive pregnant women and to adequately protect HIV-positive pregnant women. In the latter
case, given the potential impact that an effective antimalarial may have on the reduction of hos-
pital admissions, the containment of its price should not be a priority.
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graph shows the cumulative average net monetary benefits (threshold levelincremental effects
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